Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. STIVARGA (régorafénib monohydraté)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

STIVARGA (régorafénib monohydraté)

Medicine - Posted on Oct 24 2018 - Updated on Jun 12 2019
Active substance (DCI)
  • régorafénib monohydraté
history (3)
  • 1/31/18

    STIVARGA (regorafenib), tyrosine kinase inhibitor

    High clinical benefit in the treatment of hepatocellular carcinoma in patients in good general condition (ECOG 0-1), with pr...
    CAV :
    54321
    icône flèche
  • 10/7/15

    STIVARGA (regorafenib), protein kinase inhibitor

    Minor improvement in the third-line treatment of unresectable or metastatic gastrointestinal stromal tumours STIVARGA now ha...
    CAV :
    54321
    icône flèche
  • 5/14/14

    STIVARGA (regorafenib), tyrosine kinase inhibitor

    No clinical benefit demonstrated in the management of metastatic colorectal cancer Actual benefit low in patients with an EC...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01XE21
Manufacturer
BAYER HEALTHCARE SAS
Presentation

STIVARGA 40 mg, comprimé pelliculé (code CIS : 69548508)
3 flacons de 28 comprimés - Code CIP : 34009 275 200 0 6

All our publications
    Digestive system cancers Drug therapy

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
CG8bT2kBnWvdkrCf